Baqsimi
Lilly’s Baqsimi nasal powder gains FDA approval after proving non-inferior to injection
July 25, 2019Sales and Marketing Baqsimi, Eli Lilly, FDA, US, diabetes, pharma
Eli Lilly has been awarded approval from the FDA for its Baqsimi nasal powder in the treatment of severe hypoglycaemia, …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
